A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol 9401.
T cell lines generated by primary in vitro stimulation with B7-expressing HLA-A2+ melanoma cells lyse HLA-A2+ melanomas, but not non-melanomas that are HLA-A2+. Other data have demonstrated lack of response of these T cell lines against non-HLA-A2 melanomas. These concepts are verified by data from MALME MEL, which is killed, and MALME FIB, which is not. In no case was lysis directed at targets expressing potential allo-antigens (except for HLA-A2+ melanomas). A19 and Aw33 have not been excluded as possible allo-targets (but no data suggests they are). In total, it appears that much of the lytic activity observed in the two T cell lines is directed against HLA-A2-restricted, melanoma-specific antigens.
Fenton
R T
RT
Sznol
M
M
Luster
D G
DG
Taub
D D
DD
Longo
D L
DL
D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000276:immunology*; D002985:Clinical Protocols; D005260:Female; D015316:Genetic Therapy; D015788:HLA-A1 Antigen / Q000276:immunology*; D015789:HLA-A2 Antigen / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular / Q000235:genetics*; D008297:Male; D008545:Melanoma / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D008875:Middle Aged; D014162:Transfection; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm; D015788:HLA-A1 Antigen; D015789:HLA-A2 Antigen